Myopia
Conditions
Keywords
myopia control, soft contact lens, eye diseases
Brief summary
The objective of this study is to demonstrate that the Ticon Aspherical Daily Disposable Soft Contact Lens could retard myopia progress in youth
Detailed description
This study is designed as a prospective, multicenter, randomized, double blinded, controlled, paired-eye comparison study. At least 60 evaluable subjects with myopia progression ≧ 0.75 D in the past 12 months will be recruited from 2 study sites. The experimental soft contact lens with aspherical design (Ticon Aspherical) will be randomly assigned to either the right eye or the left eye of the subject , then the fellow eye will be assigned a control lens with a single vision distance (SVD) soft contact lens (Ticon). Both lenses will be worn at least 8 hours a day, 5 days a week for 1 year. All lenses will be replaced every day. Brief assessment of the clinical findings will be followed up for one year at 1 day, 1 week, 1, 3, 6, 9, 12 months upon allocation. The primary efficacy outcome is change in spherical equivalent refraction (SER) measured by cycloplegic autorefraction over 12 months. The secondary outcome is change in axial eye length (AXL) measured over 12 months. The secondary outcome measure is used to corroborate any changes in SER
Interventions
Sponsors
Study design
Intervention model description
paired-eye design
Eligibility
Inclusion criteria
* Myopia (SE) between -1.00D to -8.00D * Astigmatism less than or equal to 1.75D * Myopia progression ≧0.75 D in the past 12 months * Best Corrected Visual Acuity (BCVA): 0.9 Snellen or better * Willingness to wear contact lens constantly * Availability for follow-up for at least 1 year * Parent's understanding and acceptance * have an acceptable surrogate capable of giving legally authorized consent on behalf of the subject
Exclusion criteria
* Anisometropia greater than 2.00D * Presence of ocular disease preventing wear of contact lens * Severe ocular or systemic allergies * Taking any medication that might have an impact on contact lens wear or that might influence the outcome of the clinical trial * Ocular or systemic condition that might affect refractive development * Atropine/Pirenzepine treatment for myopia control in the past 1 month * Prior use of Ortho-K lenses * Dry eye with Schimer Test (basal secretion test) \< 5mm/5min or other physical condition that would contraindicate contact lens wear
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Spherical Equivalent Refraction (SER) | 12 months | The change in spherical equivalent refraction (SER) measured by cycloplegic autorefraction over 12 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Axial Eye Length (AXL) | 12 months | The change in axial eye length (AXL) measured over 12 months. Axial length is measured after cycloplegia using optical biometry. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Primary safety Endpoints | 12 months | All dispensed eyes over all follow-up visits. Measured on a scale of 0-4 with 0=no findings and 4=severe findings. Epithelial edema, epithelial microcysts, corneal staining, limbal & bulbar injection, conjunctival abnormalities, corneal neovascularization and infiltrates will be measured. |